Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 22, 2026 at 8:00 a.m. Pacific Time. Holders of 9,393,514 shares of common stock outstanding as of May 1, 2026 may vote online, by phone, mail, or during the webcast.
Stockholders will elect three Class III directors (Kelly A. Romano, James A. Johnson and Natalie C. Holles), ratify Ernst & Young LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and choose how often future advisory pay votes occur. The board recommends voting FOR all proposals and selecting a THREE-YEAR frequency for Say‑on‑Pay votes.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. The award vests in equal monthly installments over 36 months, contingent on her continued service as a Service Provider under the company’s 2026 Equity Incentive Plan. Following this grant, she holds 56,000 stock options directly.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. They vest monthly over 36 months, contingent on his continued service to the company.
Following this grant, Silverman holds 56,000 stock options directly, reflecting a compensation award rather than an open-market share purchase or sale.
LeonaBio, Inc. director Callori Fred received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. All 56,000 options are held directly after this award.
The options are scheduled to vest in equal installments monthly over 36 months from the grant date, as long as the director continues to serve as a service provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Peter B. Silverman filed an initial Form 3 as a reporting person for the company. The filing lists him as a director but shows no reported purchases, sales, or other transactions in LeonaBio securities, and no derivative holdings in this snapshot.
LeonaBio, Inc. filed an initial Form 3 identifying Natalie C. Holles as a director and reporting person for the company’s securities. The filing does not report any transactions or holdings, serving mainly to establish her status under insider reporting rules.
LeonaBio, Inc. director Callori Fred filed an initial Form 3 to report insider status with the company. The filing lists no stock purchases, sales, option exercises, gifts, or other transactions, indicating this is a baseline ownership disclosure rather than a record of trading activity.
Perceptive Advisors and affiliates report owning 1,882,370 shares of LeonaBio common stock, representing 19.99% of the class. The stake includes 1,552,614 shares, or 16.5%, held by Perceptive Life Sciences Master Fund, Ltd. and 352,804 shares, or 3.7%, held by Perceptive Xontogeny Venture Fund II.
The ownership percentages are based on 9,393,514 shares of common stock outstanding and give effect to warrants allowing purchase of 23,048 additional shares subject to limits. A Beneficial Ownership Limitation prevents exercises that would take the group above 19.99%. On May 5, 2026, Fred Callori, a Partner and Managing Director at Perceptive Advisors, was appointed to LeonaBio’s board of directors. The filers report no transactions in the company’s stock during the prior sixty days.
LeonaBio, Inc., a clinical-stage biopharma company, reported a net loss of $32.9M for the quarter ended March 31, 2026, compared with $9.1M a year earlier. The larger loss was driven by higher research and development spending and a $16.3M non-cash loss from remeasuring the Sermonix pre-funded warrant before it was reclassified to equity.
Research and development expenses rose to $11.3M, mainly reflecting investment in lasofoxifene and ATH-1105, while general and administrative costs increased to $6.9M. Cash, cash equivalents and investments totaled $67.7M, and management believes this will fund operations for at least 12 months based on the current plan.